SynthesisEuropean journal of nutrition2026
The impact of dietary interventions on liver health biomarkers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic literature review and meta-analysis of randomized controlled trials.
Synthesis in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease.Hepatology international · 2026Review
- Higher adherence to the EAT-lancet diet is associated with reduced risk of metabolic dysfunction-associated steatotic liver disease: a 5-year middle eastern cohort study.Diabetology & metabolic syndrome · 2026Article
- Development of the Asian Mediterranean Diet and its sensory acceptability in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).BMC nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetabolic dysfunction-associated steatotic liver disease (MASLD) and its subtype, metabolic dysfunction-associated alcohol-related liver disease (MetALD), represent the most prevalent chronic liver diseases worldwide, closely linked to unhealthy dietary patterns. Lifestyle modification is considered first-line treatment, yet the comparative effectiveness of different dietary approaches remains unclear. This systematic review and meta-analysis aimed to evaluate the impact of dietary interventions on liver health biomarkers in individuals with MASLD and MetALD.
methodsA systematic database search was conducted for randomised controlled trials (RCTs, 2018–2024). Eligible trials assessed dietary interventions in MASLD or MetALD and reported changes in alanine aminotransferase (ALT), liver stiffness, MRI-proton density fat fraction (MRI-PDFF), and controlled attenuation parameter. Data were synthesized using weighted mean differences with fixed or random effects models.
resultsSixty-eight full-text articles were included in the systematic review, of which 24 met the criteria for the meta-analysis. Since no eligible studies were identified in individuals with MetALD, the findings apply solely to people with MASLD. In studies on fasting interventions ALT (MD = − 12.47 IU/L; 95% CI − 22.03,− 2.92; p = 0.01; n = 6) and liver stiffness (MD = − 0.24 kPa; 95% CI − 0.46, − 0.03; p = 0.03; n = 4) were reduced compared to controls. The Mediterranean diet (MedDiet) resulted in significant differences in ALT (MD = − 2.93 IU/L; 95% CI − 5.68, − 0.19; p = 0.04; n = 9), liver stiffness (MD = − 0.35 kPa; 95% CI − 0.54, − 0.16; p = 0.00; n = 4), and MRI-PDFF (MD = − 1.37%; 95% CI − 2.33, − 0.40; p = 0.01; n = 5). LCHF/ketogenic diets (n = 6) and Omega-3 fatty acids supplementation (n = 4) did not significantly alter ALT.
conclusionFasting and MedDiet showed positive effects on surrogate biomarkers in MASLD. Larger, long-term isocaloric RCTs with standardized outcome reporting are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.